Huntingtin aggregation kinetics and their pathological role in a drosophila Huntington's disease model

Genetics

Volumn 190, Issue 2, 2012, Pages 581-600

  Weiss, Kurt R ^a   Kimura, Yoko ^b   Lee, Wyan Ching Mimi ^a   Littleton, J Troy ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DROSOPHILA MELANOGASTER; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HAPLOINSUFFICIENCY; HUNTINGTON CHOREA; IN VIVO STUDY; LETHALITY; MALE; NERVE DEGENERATION; NEURITE; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL LINE; CELL NUCLEUS; CHROMOSOME MAPPING; CYTOPLASM; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; EXONS; FEMALE; GENE EXPRESSION; GENES, LETHAL; GENETIC LOCI; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; KINETICS; MALE; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NEURITES; NEURONS; NUCLEAR PROTEINS; PROTEIN BINDING; SALIVARY GLANDS;

EID: 84863115461     PISSN: 00166731     EISSN: 19432631     Source Type: Journal    
DOI: 10.1534/genetics.111.133710     Document Type: Article

References (84)

1. Arrasate, M., S. Mitra, E. S. Schweitzer, M. R. Segal, and S. Finkbeiner, 2004 Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810.
2. Becher, M. W., J. A. Kotzuk, A. H. Sharp, S. W. Davies, G. P. Bates et al., 1998 Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 4: 387-397.
3. Bello, B., N. Holbro, and H. Reichert, 2007 Polycomb group genes are required for neural stem cell survival in postembryonic neurogenesis of Drosophila. Development 134: 1091-1099.
4. Biyasheva, A., T. V. Do, Y. Lu, M. Vaskova, and A. J. Andres, 2001 Glue secretion in the Drosophila salivary gland: a model for steroid-regulated exocytosis. Dev. Biol. 231: 234-251.
5. Brody, T., 1999 The interactive fly: gene networks, development and the Internet. Trends Genet. 15: 333-334.
6. Buckley, N. J., R. Johnson, C. Zuccato, A. Bithell, and E. Cattaneo, 2010 The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 39: 28-39.
7. Campbell, R. E., O. Tour, A. E. Palmer, P. A. Steinbach, G. S. Baird et al., 2002 A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. USA 99: 7877-7882.
8. Carmichael, J., J. Chatellier, A. Woolfson, C. Milstein, A. R. Fersht et al., 2000 Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. USA 97: 9701-9705.
9. Cattaneo, E., C. Zuccato, and M. Tartari, 2005 Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6: 919-930.
10. Chai, Y., J. Shao, V. M. Miller, A. Williams, and H. L. Paulson, 2002 Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc. Natl. Acad. Sci. USA 99: 9310-9315.
11. Chen, M., V. O. Ona, M. Li, R. J. Ferrante, K. B. Fink et al., 2000 Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6: 797-801.
12. Chopra, V., J. H. Fox, G. Lieberman, K. Dorsey, W. Matson et al., 2007 A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 104: 16685-16689.
13. Colby, D. W., Y. Chu, J. P. Cassady, M. Duennwald, H. Zazulak et al., 2004 Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. USA 101: 17616-17621.
14. Cummings, C. J., Y. Sun, P. Opal, B. Antalffy, R. Mestril et al., 2001 Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. 10: 1511-1518.
15. Davies, S. W., M. Turmaine, B. A. Cozens, M. DiFiglia, A. H. Sharp et al., 1997 Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
16. Dedeoglu, A., J. K. Kubilus, T. M. Jeitner, S. A. Matson, M. Bogdanov et al., 2002 Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22: 8942-8950.
17. DiFiglia, M., E. Sapp, K. O. Chase, S. W. Davies, G. P. Bates et al., 1997 Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
18. Feany, M. B., and W. W. Bender, 2000 A Drosophila model of Parkinson's disease. Nature 404: 394-398.
19. Fernandez-Funez, P., M. L. Nino-Rosales, B. de Gouyon, W. C. She, J. M. Luchak et al., 2000 Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408: 101-106.
20. Ferrante, R. J., C. A. Gutekunst, F. Persichetti, S. M. McNeil, N. W. Kowall et al., 1997 Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17: 3052-3063.
21. Fuger, P., L. B. Behrends, S. Mertel, S. J. Sigrist, and T. M. Rasse, 2007 Live imaging of synapse development and measuring protein dynamics using two-color fluorescence recovery after photo-bleaching at Drosophila synapses. Nat. Protoc. 2: 3285-3298.
22. Gafni, J., E. Hermel, J. E. Young, C. L. Wellington, M. R. Hayden et al., 2004 Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279: 20211-20220.
23. Gerber, H. P., K. Seipel, O. Georgiev, M. Hofferer, M. Hug et al., 1994 Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263: 808-811.
24. Graham, R. K., Y. Deng, E. J. Slow, B. Haigh, N. Bissada et al., 2006 Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179-1191.
25. Gunawardena, S., L. S. Her, R. G. Brusch, R. A. Laymon, I. R. Niesman et al., 2003 Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40: 25-40.
26. Harjes, P., and E. E. Wanker, 2003 The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28: 425-433.
27. Heiser, V., E. Scherzinger, A. Boeddrich, E. Nordhoff, R. Lurz et al., 2000 Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. USA 97: 6739-6744.
28. Hodgson, J. G., N. Agopyan, C. A. Gutekunst, B. R. Leavitt, F. LePiane et al., 1999 A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23: 181-192.
29. Hoffner, G., P. Kahlem, and P. Djian, 2002 Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J. Cell Sci. 115: 941-948.
30. Hoffner, G., M. L. Island, and P. Djian, 2005 Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem. 95: 125-136.
31. Huntington's Disease Research Collaboration, 1993 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72: 971-983.
32. Jackson, G. R., I. Salecker, X. Dong, X. Yao, N. Arnheim et al., 1998 Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21: 633-642.
33. Jana, N. R., M. Tanaka, G. Wang, and N. Nukina, 2000 Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9: 2009-2018.
34. Kegel, K. B., A. R. Meloni, Y. Yi, Y. J. Kim, E. Doyle et al., 2002 Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277: 7466-7476.
35. Khoshnan, A., J. Ko, and P. H. Patterson, 2002 Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 99: 1002-1007.
36. Kim, Y. J., Y. Yi, E. Sapp, Y. Wang, B. Cuiffo et al., 2001 Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA 98: 12784-12789.
37. Kimura, Y., W. C. Lee, and J. T. Littleton, 2007 Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders. Mini Rev. Med. Chem. 7: 99-106.
38. Krobitsch, S., and S. Lindquist, 2000 Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. USA 97: 1589-1594.
39. Kuemmerle, S., C. A. Gutekunst, A. M. Klein, X. J. Li, S. H. Li et al., 1999 Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46: 842-849.
40. Lajoie, P., and E. L. Snapp, 2010 Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS ONE 5: e15245.
41. Lalic, N. M., J. Maric, M. Svetel, A. Jotic, E. Stefanova et al., 2008 Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch. Neurol. 65: 476-480.
42. Lam, W., W. M. Chan, T. W. Lo, A. K. Wong, C. C. Wu et al., 2008 Human receptor for activated protein kinase C1 associ-ates with polyglutamine aggregates and modulates polyglutamine toxicity. Biochem. Biophys. Res. Commun. 377: 714-719.
43. Lecerf, J. M., T. L. Shirley, Q. Zhu, A. Kazantsev, P. Amersdorfer et al., 2001 Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98: 4764-4769.
44. Lee, W. C., M. Yoshihara, and J. T. Littleton, 2004 Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. USA 101: 3224-3229.
45. Li, H., S. H. Li, A. L. Cheng, L. Mangiarini, G. P. Bates et al., 1999 Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum. Mol. Genet. 8: 1227-1236.
46. Li, H., S. H. Li, Z. X. Yu, P. Shelbourne, and X. J. Li, 2001 Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's diseasemice. J. Neurosci. 21: 8473-8481.
47. Li, S. H., C. A. Gutekunst, S. M. Hersch, and X. J. Li, 1998 Interaction of huntingtin-associated protein with dynactin P150Glued. J. Neurosci. 18: 1261-1269.
48. Lunkes, A., K. S. Lindenberg, L. Ben-Haiem, C. Weber, D. Devys et al., 2002 Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10: 259-269.
49. Luthi-Carter, R., S. A. Hanson, A. D. Strand, D. A. Bergstrom, W. Chun et al., 2002 Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11: 1911-1926.
50. Martin, B., E. Golden, A. Keselman, M. Stone, M. P. Mattson et al., 2008 Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol. Histopathol. 23: 237-250.
51. Nagai, Y., T. Inui, H. A. Popiel, N. Fujikake, K. Hasegawa et al., 2007 A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14: 332-340.
52. Orr, H. T., and H. Y. Zoghbi, 2007 Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30: 575-621.
53. Park, J. H., A. J. Schroeder, C. Helfrich-Forster, F. R. Jackson, and J. Ewer, 2003 Targeted ablation of CCAP neuropeptide-containing neurons of Drosophila causes specific defects in execution and circadian timing of ecdysis behavior. Development 130: 2645-2656.
54. Persichetti, F., F. Trettel, C. C. Huang, C. Fraefel, H. T. Timmers et al., 1999 Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Neurobiol. Dis. 6: 364-375.
55. Portera-Cailliau, C., J. C. Hedreen, D. L. Price, and V. E. Koliatsos, 1995 Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15: 3775-3787.
56. Qin, Z. H., and Z. L. Gu, 2004 Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol. Sin. 25: 1243-1249.
57. Rieckhof, G. E., M. Yoshihara, Z. Guan, and J. T. Littleton, 2003 Presynaptic N-type calcium channels regulate synaptic growth. J. Biol. Chem. 278: 41099-41108.
58. Rigamonti, D., C. Mutti, C. Zuccato, E. Cattaneo, and A. Contini, 2009 Turning REST/NRSF dysfunction in Huntington's disease into a pharmaceutical target. Curr. Pharm. Des. 15: 3958-3967.
59. Romero, E., G. H. Cha, P. Verstreken, C. V. Ly, R. E. Hughes et al., 2008 Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57: 27-40.
60. Sanchez, I., C. Mahlke, and J. Yuan, 2003 Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421: 373-379.
61. Sapp, E., J. Penney, A. Young, N. Aronin, J. P. Vonsattel et al., 1999 Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J. Neuropathol. Exp. Neurol. 58: 165-173.
62. Scherzinger, E., R. Lurz, M. Turmaine, L. Mangiarini, B. Hollenbach et al., 1997 Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549-558.
63. Scherzinger, E., A. Sittler, K. Schweiger, V. Heiser, R. Lurz et al., 1999 Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA 96: 4604-4609.
64. Seong, I. S., J. M. Woda, J. J. Song, A. Lloret, P. D. Abeyrathne et al., 2010 Huntingtin facilitates polycomb repressive complex 2. Hum. Mol. Genet. 19: 573-583.
65. Sieradzan, K. A., A. O. Mechan, L. Jones, E. E. Wanker, N. Nukina et al., 1999 Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156: 92-99.
66. Sinadinos, C., T. Burbidge-King, D. Soh, L. M. Thompson, J. L. Marsh et al., 2009 Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol. Dis. 34: 389-395.
67. Slow, E. J., R. K. Graham, A. P. Osmand, R. S. Devon, G. Lu et al., 2005 Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 102: 11402-11407.
68. Smith, D. L., B. Woodman, A. Mahal, K. Sathasivam, S. Ghazi-Noori et al., 2003 Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol. 54: 186-196.
69. Steffan, J. S., L. Bodai, J. Pallos, M. Poelman, A. McCampbell et al., 2001 Histone deacetylase inhibitors arrest polyglutaminedependent neurodegeneration in Drosophila. Nature 413: 739-743.
70. Szebenyi, G., G. A. Morfini, A. Babcock, M. Gould, K. Selkoe et al., 2003 Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40: 41-52.
71. Tagawa, K., M. Hoshino, T. Okuda, H. Ueda, H. Hayashi et al., 2004 Distinct aggregation and cell death patterns among different types of primary neurons induced by mutant huntingtin protein. J. Neurochem. 89: 974-987.
72. Vacher, C., L. Garcia-Oroz, and D. C. Rubinsztein, 2005 Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 14: 3425-3433.
73. Velier, J., M. Kim, C. Schwarz, T. W. Kim, E. Sapp et al., 1998 Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152: 34-40.
74. Vomel, M., and C. Wegener, 2007 Neurotransmitter-induced changes in the intracellular calcium concentration suggest a differential central modulation of CCAP neuron subsets in Drosophila. Dev. Neurobiol. 67: 792-808.
75. Vonsattel, J. P., R. H. Myers, T. J. Stevens, R. J. Ferrante, E. D. Bird et al., 1985 Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44: 559-577.
76. Warrick, J. M., H. Y. Chan, G. L. Gray-Board, Y. Chai, H. L. Paulson et al., 1999 Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23: 425-428.
77. Wellington, C. L., L. M. Ellerby, C. A. Gutekunst, D. Rogers, S. Warby et al., 2002 Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22: 7862-7872.
78. Wittmann, C. W., M. F. Wszolek, J. M. Shulman, P. M. Salvaterra, J. Lewis et al., 2001 Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293: 711-714.
79. Wolfgang, W. J., T. W. Miller, J. M. Webster, J. S. Huston, L. M. Thompson et al., 2005 Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. USA 102: 11563-11568.
80. Yeo, M., S. K. Lee, B. Lee, E. C. Ruiz, S. L. Pfaff et al., 2005 Small CTD phosphatases function in silencing neuronal gene expression. Science 307: 596-600.
81. Yoshida, H., T. Yoshizawa, F. Shibasaki, S. Shoji, and I. Kanazawa, 2002 Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol. Dis. 10: 88-99.
82. Zhu, B., J. A. Pennack, P. McQuilton, M. G. Forero, K. Mizuguchi et al., 2008 Drosophila neurotrophins reveal a common mechanism for nervous system formation. PLoS Biol. 6: e284.
83. Zuccato, C., A. Ciammola, D. Rigamonti, B. R. Leavitt, D. Goffredo et al., 2001 Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498.
84. Zuccato, C., M. Tartari, A. Crotti, D. Goffredo, M. Valenza et al., 2003 Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35: 76-83.